AR110968A2 - Derivados de glicósido bencílico y composición farmacéutica - Google Patents
Derivados de glicósido bencílico y composición farmacéuticaInfo
- Publication number
- AR110968A2 AR110968A2 ARP180100299A ARP180100299A AR110968A2 AR 110968 A2 AR110968 A2 AR 110968A2 AR P180100299 A ARP180100299 A AR P180100299A AR P180100299 A ARP180100299 A AR P180100299A AR 110968 A2 AR110968 A2 AR 110968A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally
- alkyloxy
- groups
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229930182470 glycoside Natural products 0.000 title 1
- 150000002338 glycosides Chemical class 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 43
- 125000000217 alkyl group Chemical group 0.000 abstract 31
- 125000003545 alkoxy group Chemical group 0.000 abstract 25
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 19
- -1 pyrrolidin-1-ylcarbonyl Chemical group 0.000 abstract 16
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 14
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 12
- 229910052760 oxygen Inorganic materials 0.000 abstract 12
- 229910052717 sulfur Inorganic materials 0.000 abstract 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 11
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 9
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 8
- 125000000304 alkynyl group Chemical group 0.000 abstract 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 7
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 6
- 125000003282 alkyl amino group Chemical group 0.000 abstract 6
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 6
- 239000000460 chlorine Substances 0.000 abstract 6
- 229910052801 chlorine Inorganic materials 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 5
- 239000001301 oxygen Substances 0.000 abstract 5
- 239000011593 sulfur Substances 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004465 cycloalkenyloxy group Chemical group 0.000 abstract 4
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 3
- 125000004450 alkenylene group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 3
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 3
- 125000005724 cycloalkenylene group Chemical group 0.000 abstract 3
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 3
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 3
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 2
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 abstract 2
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 abstract 2
- 125000005137 alkenylsulfonyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000005139 alkynylsulfonyl group Chemical group 0.000 abstract 2
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 2
- 125000005163 aryl sulfanyl group Chemical group 0.000 abstract 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005243 carbonyl alkyl group Chemical group 0.000 abstract 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 abstract 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 2
- 125000005171 cycloalkylsulfanyl group Chemical group 0.000 abstract 2
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 abstract 2
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 abstract 2
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 abstract 2
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 abstract 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 abstract 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 1
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 1
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 abstract 1
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 abstract 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G3/00—Glycosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan compuestos que tienen un efecto inhibitorio sobre el cotransportador de glucosa dependiente de sodio SGLT. Composiciones farmacéuticas, métodos de preparación de los compuestos, intermediarios sintéticos y métodos de uso de los compuestos, en forma independiente o en combinación con otros agentes terapéuticos, para tratar enfermedades y condiciones patológicas afectadas por la inhibición del SGLT. Reivindicación 1: Un compuesto que tiene la fórmula (1), donde A es un miembro seleccionado del grupo que consiste en oxígeno; azufre; SO; SO₂; metileno opcionalmente sustituido con uno o dos sustituyentes independientemente seleccionados entre halo, hidroxi, alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆ y cicloalquiloxi C₃₋₆; 1,1-cicloalquileno C₃₋₅ opcionalmente sustituido con uno o dos sustituyentes independientemente seleccionados entre halo, alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆ y cicloalquiloxi C₃₋₆; y NRᵃ; V es un miembro seleccionado del grupo que consiste en oxígeno; azufre; SO; SO₂; y un enlace simple; W es un miembro seleccionado del grupo que consiste en alquileno C₁₋₆, alquenileno C₂₋₆, alquinileno C₂₋₆, cicloalquileno C₃₋₁₀ y cicloalquenileno C₅₋₁₀; donde cada grupo alquileno, alquenileno, alquinileno, cicloalquileno y cicloalquenileno de W está opcionalmente fluorado en forma parcial o completa y está opcionalmente mono o disustituido con sustituyentes idénticos o diferentes seleccionados entre cloro, hidroxi, alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆, cicloalquiloxi C₃₋₆, cicloalquenilo C₅₋₁₀ y cicloalqueniloxi C₅₋₁₀, y en los grupos cicloalquileno y cicloalquenileno de W, uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí por O, S, CO, SO, SO₂ o NRᵇ, y uno o dos grupos metino de W están opcionalmente reemplazados por N; X es (i) es un miembro seleccionado entre el grupo que consiste en oxígeno; azufre; SO; y SO₂; o (ii) NRᵃ; cuando X es (i), Y es un miembro seleccionado del grupo que consiste en alquilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₀, cicloalquenilo C₅₋₁₀, (cicloalquenil C₅₋₁₀)alquilo C₁₋₃, (cicloalquil C₃₋₁₀)alquenilo C₂₋₄, cicloalquilidenmetilo C₃₋₆, (cicloalquenil C₅₋₁₀)alquenilo C₂₋₄, (alquiloxi C₁₋₄)alquilo C₁₋₃, (alqueniloxi C₂₋₄)alquilo C₁₋₃, (cicloalquiloxi C₃₋₁₀)alquilo C₁₋₃, (cicloalqueniloxi C₅₋₁₀)alquilo C₁₋₃, (alquilamino C₁₋₄)alquilo C₁₋₃, di-(alquilamino C₁₋₆)alquilo C₁₋₃, (alquil C₁₋₆)carbonilalquilo C₁₋₃, (alquenilo C₂₋₆)carbonilalquilo C₁₋₃, (alquinil C₂₋₆)carbonilalquilo C₁₋₃, (arilcarbonil)alquilo C₁₋₃, (heteroarilcarbonil)alquilo C₁₋₃, (alquilsulfonil C₁₋₆)alquilo C₁₋₃, (alquenilsulfonil C₂₋₆)alquilo C₁₋₃, (alquinilsulfonil C₂₋₆)alquilo C₁₋₃, (arilsulfonil)alquilo C₁₋₃, (heteroarilsulfonil)alquilo C₁₋₃, (alquil C₁₋₆)aminocarbonilalquilo C₁₋₃, (alquenilo C₂₋₆)aminocarbonilalquilo C₁₋₃, (alquinil C₂₋₆)aminocarbonilalquilo C₁₋₃, (arilaminocarbonil)alquilo C₁₋₃, (heteroarilaminocarbonil)alquilo C₁₋₃, (alquil)carbonilo C₁₋₆, (alquenilo)carbonilo C₂₋₆, (alquinil)carbonilo C₂₋₆, arilcarbonilo y heteroarilcarbonilo; donde los grupos o las porciones alquilo, alquenilo, alquinilo, cicloalquilo y cicloalquenilo de Y están opcionalmente fluorados en forma parcial o completa y opcionalmente están mono- o disustituidos con sustituyentes idénticos o diferentes seleccionados entre el grupo que consiste en cloro, hidroxi, alquilo C₁₋₃, alcoxi C₁₋₃, cicloalquilo C₃₋₆, cicloalquiloxi C₃₋₆, cicloalquenilo C₅₋₁₀, cicloalqueniloxi C₅₋₁₀, y NRᵇRᶜ, y en grupos o porciones cicloalquilo y cicloalquenilo de Y, uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí con O, S, CO, SO, SO₂ o NRᵇ, y uno o dos grupos metileno están opcionalmente reemplazados por N, donde el heterociclo formado por dicho reemplazo opcional es diferente de heteroarilo, y donde cuando V es un miembro seleccionado del grupo que consiste en oxígeno, azufre y un enlace simple y W es un miembro seleccionado del grupo que consiste en alquileno C₁₋₆, alquenileno C₂₋₆ y alquinileno C₂₋₆, luego Y es diferente de alquilo C₁₋₆; cuando X es (ii), Y es un miembro seleccionado del grupo que consiste en alquilsulfonilo C₁₋₆, alquenilsulfonilo C₂₋₆, alquinilsulfonilo C₂₋₆, arilsulfonilo, heteroarilsulfonilo, alquilsulfinilo C₁₋₆, arilsulfinilo, heteroarilsulfinilo, (alquil C₁₋₆)carbonilo, (alquenilo)carbonilo C₂₋₆, (alquinil)carbonilo C₂₋₆, arilcarbonilo, heteroarilcarbonilo, (alquil)aminocarbonilo C₁₋₆, (alquenilo)aminocarbonilo C₂₋₆, (alquinil)aminocarbonilo C₂₋₆, arilaminocarbonilo, heteroarilaminocarbonilo, (alquilsulfonil C₁₋₆)alquilo C₁₋₃, (alquenilsulfonil C₂₋₆)alquilo C₁₋₃, (alquinilsulfonil C₂₋₆)alquilo C₁₋₃, (arilsulfonil)alquilo C₁₋₃, (heteroarilsulfonil)alquilo C₁₋₃, (alquilsulfinil C₁₋₆)alquilo C₁₋₃, (arilsulfinil)alquilo C₁₋₃, (heteroarilsulfinil)alquilo C₁₋₃, (alquil)aminocarbonil C₁₋₆alquilo C₁₋₃, (alquenilo C₂₋₆)aminocarbonil-alquilo C₁₋₃, (alquinil C₂₋₆)aminocarbonil-alquilo C₁₋₃, (arilaminocarbonil)alquilo C₁₋₃ y (heteroarilaminocarbonil)alquilo C₁₋₃; donde las porciones alquilo, alquenilo y alquinilo de Y están opcionalmente fluoradas en forma parcial o completa, y cuando Rᵃ es H o (alquil)carbonilo C₁₋₄, entonces Y es diferente de (alquil)carbonilo C₁₋₆ o arilcarbonilo; Z es un miembro seleccionado del grupo que consiste en oxígeno; azufre; SO; SO₂; 1,1-ciclopropileno; carbonilo; y metileno opcionalmente sustituido con uno o dos sustituyentes independientemente seleccionados entre el grupo que consiste en halo, hidroxi, alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆ y cicloalquiloxi C₃₋₆; R¹ es un miembro seleccionado del grupo que consiste en hidrógeno, halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₀, (cicloalquil C₃₋₁₀)alquilo C₁₋₃, (alquenilo C₂₋₄)alquiloxi C₁₋₃, (alquinil C₂₋₄)alquiloxi C₁₋₃, (cicloalquil C₃₋₁₀)alquenilo C₂₋₄, cicloalquilidenmetilo C₃₋₆, (cicloalquiloxi C₃₋₁₀)alquilo C₁₋₃, cicloalquenilo C₅₋₁₀, (cicloalquenil C₅₋₁₀)alquilo C₁₋₃, (alquiloxi C₁₋₄)alquilo C₁₋₃, (alquilamino C₁₋₄)alquilo C₁₋₃, di-(alquilamino C₁₋₃)alquilo C₁₋₃, arilo, heteroarilo, (alquil)carbonilo C₁₋₄, arilcarbonilo, heteroarilcarbonilo, hidroxicarbonilo, aminocarbonilo, (alquil)aminocarbonilo C₁₋₄, di-(alquil)aminocarbonilo C₁₋₃, pirrolidin-1-ilcarbonilo, piperidin-1-ilcarbonilo, morfolin-4-ilcarbonilo, piperazin-1-ilcarbonilo, 4-(alquil C₁₋₄)piperazin-1-ilcarbonilo, (alquiloxi)carbonilo C₁₋₄, amino, alquilamino C₁₋₄, di-(alquil)amino C₁₋₃, pirrolidin-1-ilo, piperidin-1-ilo, morfolin-4-ilo, piperazin-1-ilo, 4-(alquil C₁₋₄)piperazin-1-ilo, (alquil)carbonilamino C₁₋₄, arilcarbonilamino, alquilsulfonilamino C₁₋₄, arilsulfonilamino, heteroarilcarbonilamino, alquiloxi C₁₋₆, cicloalquiloxi C₃₋₁₀, cicloalqueniloxi C₅₋₇, ariloxi, heteroariloxi, (aril)alquiloxi C₁₋₃, (heteroaril)alquiloxi C₁₋₃, alquilsulfanilo C₁₋₄, alquilsulfinilo C₁₋₄, alquilsulfonilo C₁₋₄, cicloalquilsulfanilo C₃₋₁₀, cicloalquilsulfinilo C₃₋₁₀, cicloalquilsulfonilo C₃₋₁₀, cicloalquenilsulfanilo C₅₋₁₀, cicloalquenilsulfinilo C₅₋₁₀, cicloalquenilsulfonilo C₅₋₁₀, arilsulfanilo, arilsulfinilo, arilsulfonilo, hidroxi, ciano y nitro; donde los grupos o las porciones alquilo, alquenilo, alquinilo, cicloalquilo y cicloalquenilo de R¹ están opcionalmente fluorados en forma parcial o completa y están opcionalmente mono- o disustituidos con sustituyentes idénticos o diferentes seleccionados entre el grupo que consiste en cloro, hidroxi, alcoxi C₁₋₃ y alquilo C₁₋₃, y en los grupos o las porciones cicloalquilo y cicloalquenilo de R¹, uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí por O, S, CO, SO o SO₂, y en los grupos o las porciones N-heterocicloalquilo de R¹, un grupo metileno está opcionalmente reemplazado con CO o SO₂; R² es un miembro seleccionado del grupo que consiste en hidrógeno, halo, hidroxi, alquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₀, cicloalquenilo C₅₋₁₀, alquiloxi C₁₋₄, cicloalquiloxi C₃₋₁₀, ciano y nitro; donde los grupos o las porciones alquilo y cicloalquilo de R² están opcionalmente mono- o polisustituidos con flúor, o en el caso que R¹ y R² están unidos por átomos de C adyacentes del anillo fenilo, R¹ y R² están opcionalmente unidos juntos para formar un puente alquileno C₃₋₅, alquenileno C₃₋₅ o butadienileno, que está opcionalmente fluorados en forma parcial o completa y opcionalmente mono- o disustituidos con sustituyentes idénticos o diferentes seleccionados entre cloro, hidroxi, alcoxi C₁₋₃ y alquilo C₁₋₃, y donde uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí con O, S, CO, SO, SO₂ o NRᵇ, y donde uno o dos grupos metino opcionalmente pueden estar reemplazados con N; R³ es un miembro seleccionado del grupo que consiste en hidrógeno, halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₀, (cicloalquil C₃₋₁₀)alquilo C₁₋₃, cicloalquenilo C₅₋₁₀, (cicloalquenil C₅₋₁₀)alquilo C₁₋₃, (alquiloxi C₁₋₄)alquilo C₁₋₃, (cicloalquiloxi C₃₋₁₀)alquilo C₁₋₃, (alquilamino C₁₋₄)alquilo C₁₋₃, di-(alquilamino C₁₋₃)alquilo C₁₋₃, (cicloalquil C₃₋₁₀)alquenilo C₂₋₄, cicloalquilidenmetilo C₃₋₆, arilo, heteroarilo, (alquil)carbonilo C₁₋₄, arilcarbonilo, heteroarilcarbonilo, aminocarbonilo, (alquil C₁₋₄)aminocarbonilo, di-(alquil C₁₋₃)aminocarbonilo, pirrolidin-1-ilcarbonilo, piperidin-1-ilcarbonilo, morfolin-4-ilcarbonilo, piperazin-1-ilcarbonilo, 4-(alquil C₁₋₄)piperazin-1-ilcarbonilo, hidroxicarbonilo, (alquiloxi C₁₋₄)carbonilo, alquilamino C₁₋₄, di-(alquil C₁₋₃)amino, pirrolidin-1-ilo, piperidin-1-ilo, morfolin-4-ilo, piperazin-1-ilo, 4-(alquil C₁₋₄)piperazin-1-ilo, (alquil C₁₋₄)carbonilamino, arilcarbonilamino, heteroaril-carbonilamino, alquilsulfonilamino C₁₋₄, arilsulfonilamino, alquiloxi C₁₋₆, cicloalquiloxi C₃₋₁₀, cicloalqueniloxi C₅₋₇, ariloxi, heteroariloxi, (alquenilo C₂₋₄)alquiloxi C₁₋₃, (alquinil C₂₋₄)alquiloxi C₁₋₃, (aril)alquiloxi C₁₋₃, (heteroaril)alquiloxi C₁₋₃, alquilsulfanilo C₁₋₄, alquilsulfinilo C₁₋₄, alquilsulfonilo C₁₋₄, cicloalquilsulfanilo C₃₋₁₀, cicloalquilsulfinilo C₃₋₁₀, cicloalquilsulfonilo C₃₋₁₀, cicloalquenilsulfanilo C₅₋₁₀, cicloalquenilsulfinilo C₅₋₁₀, cicloalquenilsulfonilo C₅₋₁₀, arilsulfanilo, arilsulfinilo, arilsulfonilo, amino, hidroxi, ciano y nitro; donde los grupos o las porciones de alquilo, alquenilo, alquinilo, cicloalquilo y cicloalquenilo de R³ están opcionalmente fluorados en forma parcial o completa y están opcionalmente mono- o disustituidos con sustituyentes idénticos o diferentes seleccionados entre cloro, hidroxi, alcoxi C₁₋₃ y alquilo C₁₋₃, y en los grupos o las porciones cicloalquilo y cicloalquenilo de R³, uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí con O, S, CO, SO o SO₂, y en los grupos o las porciones N-heterocicloalquilo de R³, un grupo metileno esta opcionalmente reemplazado por CO o SO₂; R⁴ es un miembro seleccionado del grupo que consiste en hidrógeno, halo, ciano, nitro, hidroxi, alquilo C₁₋₃, cicloalquilo C₃₋₁₀, alquiloxi C₁₋₃ o cicloalquiloxi C₃₋₁₀, donde los grupos o las porciones alquilo y cicloalquilo de R⁴ están opcionalmente mono- o polisustituidos con flúor, y cuando R³ y R⁴ están unidos por átomos de C adyacentes del anillo fenilo, R³ y R⁴ opcionalmente se unen para formar un puente alquileno C₃₋₅, alquenileno C₃₋₅ o butadienileno que está opcionalmente fluorado en forma parcial o completa y está opcionalmente mono- o disustituido con sustituyentes idénticos o diferentes seleccionados entre cloro, hidroxi, alcoxi C₁₋₃ y alquilo C₁₋₃, y donde uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí con O, S, CO, SO, SO₂ o NRᵇ, y donde uno o dos grupos metino están opcionalmente reemplazados por N; R⁵ es un miembro seleccionado del grupo que consiste en hidrógeno, halo, ciano, nitro, hidroxi, alquilo C₁₋₃, cicloalquilo C₃₋₁₀ y alquiloxi C₁₋₃, donde los grupos o las porciones alquilo y cicloalquilo de R⁵ están opcionalmente mono- o polisustituidos con flúor; cada R⁶, R⁷, R⁸ y R⁹ se seleccionan independientemente entre el grupo que consiste en hidroxi, (alquil C₁₋₁₈)carboniloxi, (alquil C₁₋₁₈)oxicarboniloxi, arilcarboniloxi, aril-(alquil C₁₋₃)carboniloxi, (cicloalquil C₃₋₁₀)carboniloxi, hidrógeno, halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, (cicloalquil C₃₋₁₀)alquilo C₁₋₃, (cicloalquenil C₅₋₇)alquilo C₁₋₃, arilalquilo C₁₋₃, heteroaril-alquilo C₁₋₃, alquiloxi C₁₋₆, alqueniloxi C₂₋₆, alquiniloxi C₂₋₆, cicloalquiloxi C₃₋₇, cicloalqueniloxi C₅₋₇, ariloxi, heteroariloxi, (cicloalquilo C₃₋₇)alquiloxi C₁₋₃, (cicloalquenil C₅₋₇)alquiloxi C₁₋₃, aril-alquiloxi C₁₋₃, heteroarilalquiloxi C₁₋₃, aminocarbonilo, hidroxicarbonilo, (alquil C₁₋₄)aminocarbonilo, di-(alquil C₁₋₃)aminocarbonilo, (alquiloxi C₁₋₄)carbonilo, aminocarbonil-alquilo C₁₋₃, (alquil C₁₋₄)aminocarbonil-alquilo C₁₋₃, di-(alquil C₁₋₃)aminocarbonil-alquilo C₁₋₃, hidroxicarbonil-alquilo C₁₋₃, (alquiloxi C₁₋₄)carbonil-alquilo C₁₋₃, (cicloalquiloxi C₃₋₇)alquilo C₁₋₃, (cicloalqueniloxi C₅₋₇)alquilo C₁₋₃, ariloxi-alquilo C₁₋₃, heteroariloxi-alquilo C₁₋₃, alquilsulfoniloxi C₁₋₄, arilsulfoniloxi, aril-alquil C₁₋₃-sulfoniloxi, trimetilsililoxi, t-butildimetilsililoxi, y ciano; donde los grupos o las porciones alquilo, alquenilo, alquinilo, cicloalquilo y cicloalquenilo de R⁶, R⁷, R⁸ y R⁹ están opcionalmente fluorados en forma parcial o completa y están opcionalmente mono- o disustituidos con sustituyentes idénticos o diferentes seleccionados entre el grupo que consiste en cloro, hidroxi, alcoxi C₁₋₃ y alquilo C₁₋₃, y en los grupos o las porciones cicloalquilo y cicloalquenilo de R⁶, R⁷, R⁸ y R⁹, uno o dos grupos metileno están opcionalmente reemplazados independientemente entre sí con NRᵇ, O, S, CO, SO o SO₂; cada Rᵃ es un miembro seleccionado independientemente del grupo que consiste en H, alquilo C₁₋₆, cicloalquilo C₃₋₆ y (alquil C₁₋₄)carbonilo, donde los grupos o las porciones alquilo y cicloalquilo de Rᵃ están opcionalmente fluorados en forma parcial o completa; cada Rᵇ es un miembro seleccionado independientemente del grupo que consiste en H, alquilo C₁₋₄ y (alquil C₁₋₄)carbonilo, donde los grupos o las porciones alquilo de Rᵇ están opcionalmente fluorados en forma parcial o completa; cada Rᶜ es un miembro seleccionado independientemente del grupo que consiste en H, alquilo C₁₋₄, cicloalquilo C₃₋₆, CHRᵈRᵉ, SO₂Rᵈ, C(O)ORᵈ y C(O)NRᵈRᵉ, donde los grupos alquilo y cicloalquilo de Rᶜ están opcionalmente fluorados en forma parcial o completa; y cada Rᵈ y Rᵉ representa de modo independiente H o alquilo C₁₋₆, donde los grupos alquilo de Rᵈ y Rᵉ están opcionalmente fluorados en forma parcial o completa; y sus sales aceptables para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90967207P | 2007-04-02 | 2007-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110968A2 true AR110968A2 (es) | 2019-05-22 |
Family
ID=39795470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101366A AR065913A1 (es) | 2007-04-02 | 2008-04-01 | Derivados de glicosido bencilico, composicion y combinacion farmaceutica y uso |
| ARP180100299A AR110968A2 (es) | 2007-04-02 | 2018-02-08 | Derivados de glicósido bencílico y composición farmacéutica |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101366A AR065913A1 (es) | 2007-04-02 | 2008-04-01 | Derivados de glicosido bencilico, composicion y combinacion farmaceutica y uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7838498B2 (es) |
| EP (1) | EP2064222B1 (es) |
| JP (1) | JP5583003B2 (es) |
| KR (1) | KR101506935B1 (es) |
| CN (2) | CN104803957A (es) |
| AR (2) | AR065913A1 (es) |
| AU (1) | AU2008232419B2 (es) |
| BR (1) | BRPI0809607A2 (es) |
| CA (1) | CA2682202C (es) |
| DK (1) | DK2064222T3 (es) |
| ES (1) | ES2466672T3 (es) |
| HK (1) | HK1212982A1 (es) |
| IL (1) | IL201065A (es) |
| RU (1) | RU2492175C2 (es) |
| TW (1) | TWI405575B (es) |
| WO (1) | WO2008122014A1 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| AU2009270936B2 (en) * | 2008-07-15 | 2014-12-18 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
| CN103910702A (zh) * | 2008-08-22 | 2014-07-09 | 泰拉科斯有限公司 | 制备sglt2抑制剂的方法 |
| US8778998B2 (en) * | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| AR079438A1 (es) | 2009-12-09 | 2012-01-25 | Panacea Biotec Ltd | Derivados de azucar, composiciones farmaceuticas y sus usos |
| US20110160143A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Psoriasis Compositions |
| CN102134226B (zh) * | 2010-01-26 | 2013-06-12 | 天津药物研究院 | 一类苯基c-葡萄糖苷衍生物、其制备方法和用途 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
| EP2612669A4 (en) | 2010-08-31 | 2014-05-14 | Snu R&Db Foundation | USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST |
| WO2012109996A1 (zh) | 2011-02-18 | 2012-08-23 | 上海璎黎科技有限公司 | 一种芳基糖苷类化合物及其制备方法和应用 |
| CN102675378A (zh) * | 2011-03-09 | 2012-09-19 | 天津药物研究院 | 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9018249B2 (en) | 2011-09-13 | 2015-04-28 | Panacea Biotec Limited | SGLT inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013152476A1 (en) | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
| CN103910769B (zh) | 2012-12-31 | 2018-10-02 | 上海璎黎药业有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| CN104387428A (zh) * | 2014-12-09 | 2015-03-04 | 济南卡博唐生物科技有限公司 | 一种制备3,5,6-三-氧-苄基-1,2-异丙叉基-d-葡萄糖的方法 |
| CN104478967A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含腈基苯噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| ES2967863T3 (es) | 2015-10-23 | 2024-05-06 | B3Ar Therapeutics Inc | Ion dipolar de solabegron y usos del mismo |
| CN105770861B (zh) * | 2016-04-08 | 2020-02-28 | 吴一行 | 一种用于治疗男性糖尿病患者勃起功能障碍的药物 |
| JP7160821B2 (ja) * | 2017-02-24 | 2022-10-25 | ドン－ア エスティ カンパニー リミテッド | Ｓｇｌｔ－２阻害剤である新規グルコース誘導体 |
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| CN110551088B (zh) * | 2018-06-01 | 2022-10-21 | 北京惠之衡生物科技有限公司 | 氘修饰的苄基-4-氯苯基的c-糖苷衍生物 |
| CN112294787B (zh) * | 2020-11-17 | 2021-10-19 | 四川大学华西医院 | 一种治疗肝癌的联合用药物 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933438A (en) | 1984-02-29 | 1990-06-12 | University Of Florida | Brain-specific analogues of centrally acting amines |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| EP0576592B1 (en) * | 1991-03-18 | 2000-05-31 | The Scripps Research Institute | Oligosaccharide enzyme substrates and inhibitors: methods and compositions |
| WO1992020327A1 (en) | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| FR2710265B1 (fr) | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| DE19541260A1 (de) | 1995-11-06 | 1997-05-07 | Lohmann Therapie Syst Lts | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US6224036B1 (en) | 1997-01-17 | 2001-05-01 | Applied Power Inc. | Concrete reinforcement cable tensioner |
| CN1277550A (zh) | 1997-09-11 | 2000-12-20 | 尼科梅德丹麦有限公司 | 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物 |
| US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6607751B1 (en) | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6248864B1 (en) | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
| US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| EP1121104B1 (en) | 1998-10-01 | 2005-01-12 | Novartis AG | New controlled release oral formulations for rivastigmine |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2792527B1 (fr) | 1999-04-22 | 2004-08-13 | Ethypharm Lab Prod Ethiques | Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques |
| US6541020B1 (en) | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
| US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| EP1207860B1 (en) | 1999-09-02 | 2007-10-24 | Nostrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
| US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6080736A (en) | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| WO2001047501A1 (en) | 1999-12-29 | 2001-07-05 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| US6482440B2 (en) | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| EP1340749A4 (en) | 2000-11-17 | 2007-09-05 | Takeda Pharmaceutical | ISOXAZOLE DERIVATIVES |
| ES2287826T3 (es) * | 2000-12-20 | 2007-12-16 | Schering Corp | 2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos. |
| US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| RU2356906C2 (ru) | 2002-08-08 | 2009-05-27 | Киссеи Фармасьютикал Ко., Лтд. | Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения |
| RU2322449C2 (ru) | 2002-08-09 | 2008-04-20 | Тайсо Фармасьютикал Ко., Лтд. | ПРОИЗВОДНЫЕ АРИЛ 5-ТИО-β-D-ГЛЮКОПИРАНОЗИДА И ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА ПРИ ДИАБЕТЕ, СОДЕРЖАЩИЕ ИХ |
| DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| ES2363941T3 (es) | 2003-03-14 | 2011-08-19 | Astellas Pharma Inc. | Derivados de c-glucósido para el tratamiento de diabetes. |
| JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| JP2004359630A (ja) * | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | ジフルオロジフェニルメタン誘導体及びその塩 |
| EP1679965A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES |
| WO2005012242A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica Nv | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides |
| ES2531660T3 (es) | 2003-08-01 | 2015-03-18 | Mitsubishi Tanabe Pharma Corporation | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| US7371732B2 (en) | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
| BRPI0508259A (pt) | 2004-03-04 | 2007-07-31 | Kissei Pharmaceutical | derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo |
| CN103030617A (zh) | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TW200606129A (en) * | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| DE602005009745D1 (de) * | 2004-12-16 | 2008-10-23 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| ATE453656T1 (de) | 2005-04-15 | 2010-01-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren |
-
2008
- 2008-04-01 JP JP2010502246A patent/JP5583003B2/ja not_active Expired - Fee Related
- 2008-04-01 BR BRPI0809607-4A patent/BRPI0809607A2/pt not_active IP Right Cessation
- 2008-04-01 WO PCT/US2008/059047 patent/WO2008122014A1/en not_active Ceased
- 2008-04-01 RU RU2009140298/04A patent/RU2492175C2/ru not_active IP Right Cessation
- 2008-04-01 CN CN201510041214.8A patent/CN104803957A/zh active Pending
- 2008-04-01 AU AU2008232419A patent/AU2008232419B2/en not_active Ceased
- 2008-04-01 CN CN200880011535A patent/CN101652377A/zh active Pending
- 2008-04-01 US US12/060,767 patent/US7838498B2/en not_active Expired - Fee Related
- 2008-04-01 CA CA2682202A patent/CA2682202C/en not_active Expired - Fee Related
- 2008-04-01 AR ARP080101366A patent/AR065913A1/es not_active Application Discontinuation
- 2008-04-01 EP EP08744883.3A patent/EP2064222B1/en active Active
- 2008-04-01 KR KR1020097022926A patent/KR101506935B1/ko not_active Expired - Fee Related
- 2008-04-01 DK DK08744883.3T patent/DK2064222T3/da active
- 2008-04-01 ES ES08744883.3T patent/ES2466672T3/es active Active
- 2008-04-02 TW TW097112029A patent/TWI405575B/zh not_active IP Right Cessation
-
2009
- 2009-09-21 IL IL201065A patent/IL201065A/en active IP Right Grant
-
2016
- 2016-01-29 HK HK16101045.5A patent/HK1212982A1/zh unknown
-
2018
- 2018-02-08 AR ARP180100299A patent/AR110968A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2466672T3 (es) | 2014-06-10 |
| CN104803957A (zh) | 2015-07-29 |
| US20080242596A1 (en) | 2008-10-02 |
| HK1212982A1 (zh) | 2016-06-24 |
| CA2682202C (en) | 2016-01-12 |
| EP2064222B1 (en) | 2014-05-07 |
| TWI405575B (zh) | 2013-08-21 |
| IL201065A (en) | 2015-09-24 |
| BRPI0809607A2 (pt) | 2014-09-30 |
| TW200846012A (en) | 2008-12-01 |
| CA2682202A1 (en) | 2008-10-09 |
| AR065913A1 (es) | 2009-07-08 |
| CN101652377A (zh) | 2010-02-17 |
| RU2009140298A (ru) | 2011-05-10 |
| DK2064222T3 (da) | 2014-07-21 |
| EP2064222A1 (en) | 2009-06-03 |
| RU2492175C2 (ru) | 2013-09-10 |
| JP5583003B2 (ja) | 2014-09-03 |
| IL201065A0 (en) | 2010-05-17 |
| US7838498B2 (en) | 2010-11-23 |
| KR101506935B1 (ko) | 2015-03-31 |
| AU2008232419B2 (en) | 2013-06-20 |
| EP2064222A4 (en) | 2011-12-14 |
| WO2008122014A1 (en) | 2008-10-09 |
| JP2010523583A (ja) | 2010-07-15 |
| KR20100016151A (ko) | 2010-02-12 |
| AU2008232419A1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110968A2 (es) | Derivados de glicósido bencílico y composición farmacéutica | |
| AR110796A2 (es) | Derivados de bencilbenceno | |
| AR127309A2 (es) | Derivados de piridazinona | |
| ECSP12011838A (es) | Derivados de la cromenona con actividad anti-tumoral | |
| PE20130774A1 (es) | Compuestos heterociclicos activadores de ampk y metodos para emplearlos | |
| NO20064599L (no) | Substituerte morfolin- og tiomorfolinderivater | |
| NO20071593L (no) | Pyrimidinderivater | |
| UY28578A1 (es) | Derivados de amida | |
| BRPI0611798A2 (pt) | compostos de arilpirazàis substituÍdos, sua composiÇço farmacÊutica e uso | |
| PA8783401A1 (es) | Derivados de piperidina/piperazina | |
| AR071268A1 (es) | Derivados de bencilfenilciclohexano, metodos de uso y una composicion farmaceutica | |
| CR10614A (es) | Derivados heterociclicos fusionados y metodos de uso | |
| UY28526A1 (es) | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos | |
| NO20054312L (no) | HIV-replikasjonsinhiberende pyrimidiner og triaziner | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR029740A1 (es) | Compuestos derivados de la n-(4-carbamimidoil-fenil)-glicina ,su uso , procedimiento de obtencion de los mismos, preparados farmaceuticos que los contienen y compuestos derivados de la n-(4-ciano-fenil)-glicina | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| AR092490A2 (es) | Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa | |
| MX2009011964A (es) | Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico. | |
| AR071523A1 (es) | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
| AR060651A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| NO20063676L (no) | Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |